XSNX Company Profile and Key Details

Q: Who are the executives of XSNX?

Mr. Neil J. LairdChief Financial OfficerDr. Christopher Wheeler Ph.D.Pres of Stemvax TherapeuticsDr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D.Chief Executive Officer & Director

PNK : XSNX

NovAccess Global

$0.01

-0.002-13.79%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

NovAccess Global Inc. (XSNX) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.00 during the session.

Stock Snapshot

0.0002

Prev. Close

12.33K

Market Cap

0.0002

Day Low

N/A

P/E Ratio

-0.18129

EPS (TTM)

-0.02

Cash Flow per Share

Open

61.65M

Number of Shares

0.0002

Day High

42.7%

Free Float in %

-0.28

Book Value

10K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 11, 2026	0.00	0.00	0.00	0.00	10K
Sep 08, 2026	0.00	0.00	0.00	0.00	268
Aug 18, 2026	0.00	0.00	0.00	0.00	183
Aug 11, 2026	0.00	0.00	0.00	0.00	10K
Jul 02, 2026	0.00	0.00	0.00	0.00	431
Jun 22, 2026	0.00	0.00	0.00	0.00	2.94K
Jun 15, 2026	0.00	0.00	0.00	0.00	553
Jun 05, 2026	0.00	0.00	0.00	0.00	170
Jun 04, 2026	0.00	0.00	0.00	0.00	11.63K
May 18, 2026	0.00	0.00	0.00	0.00	250
Apr 17, 2026	0.00	0.00	0.00	0.00	235
Apr 07, 2026	0.00	0.00	0.00	0.00	19.82K
Apr 06, 2026	0.00	0.00	0.00	0.00	146
Mar 30, 2026	0.00	0.00	0.00	0.00	8.7K
Feb 27, 2026	0.00	0.00	0.00	0.00	33.01K
Feb 12, 2026	0.00	0.00	0.00	0.00	500
Feb 06, 2026	0.00	0.00	0.00	0.00	4.32K
Feb 02, 2026	0.00	0.00	0.00	0.00	352
Jan 22, 2026	0.00	0.00	0.00	0.00	3K
Jan 06, 2026	0.00	0.00	0.00	0.00	500

Contact Details

New York, NY 10024

United States

https://novaccessglobal.com 440 644 1027

About Company

Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00

Company Overview

The stock is currently mid-range between its 52-week high and low $0.00 and $0.05. With a market capitalization of about $12.33 thousand, NovAccess Global Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.80). Key stats such as the average daily volume over the past year has been around 1.12 thousand shares, trading with heavier-than-usual volume. Headquartered in New York, NY, NovAccess Global Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dwain K. Morris-Irvin, the company employs approximately 2 people and listed since September 21, 1998. Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States.

Technical Performance

Average 10-day trading volume of 5.13 thousand shares is slightly above the 3-month average of 3.48 thousand, indicating heightened recent market interest.

Valuation Metrics

NovAccess Global Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.02, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Financial & Profitability Overview

Over the trailing twelve months, NovAccess Global has not generated any revenue. Returns are negative, with ROA at -7590.52% and ROE at 60.59%.
On valuation metrics, NovAccess Global trades at a P/E of -0.00, P/S of 0.00 and P/B of -0.00. Liquidity is tight, with a current ratio of 0.01 and quick ratio of 0.01. Debt-to-equity is -0.28, supported by a cash flow-to-debt ratio of -0.28.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2023, NovAccess Global posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $2.47M (margin 0.0%). Net income was- $4.72M (EPS - $0.23).
The company ended the quarter with $21.42K in cash and short-term investments, a total debt of $2.20M, and net debt of $2.18M. Total assets were $62.25K, with equity of - $7.80M. Financials further reflected weakness, with operating cash flow of - $624.64K, free cash flow of - $624.64K, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that NovAccess Global Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows NovAccess Global Inc. trading at a premium to the broader market with a P/E of -0.0.

Frequently Asked Questions

What is the current NovAccess Global Inc. (XSNX) stock price?

NovAccess Global Inc. (OTC: XSNX) stock price is $0.00 in the last trading session. During the trading session, XSNX stock reached the peak price of $0.00 while $0.00 was the lowest point it dropped to. The percentage change in XSNX stock occurred in the recent session was 0% while the dollar amount for the price change in XSNX stock was $0.00.

XSNX's industry and sector of operation?

The OTC listed XSNX is part of Biotechnology industry that operates in the broader Healthcare sector. NovAccess Global Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XSNX?

Mr. Neil J. Laird
Chief Financial Officer
Dr. Christopher Wheeler Ph.D.
Pres of Stemvax Therapeutics
Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D.
Chief Executive Officer & Director

How XSNX did perform over past 52-week?

XSNX's closing price is 237.84% higher than its 52-week low of $0.00 where as its distance from 52-week high of $0.05 is -92.42%.

How many employees does XSNX have?

Number of XSNX employees currently stands at 2.

Link for XSNX official website?

Official Website of XSNX is: https://novaccessglobal.com

How do I contact XSNX?

XSNX could be contacted at phone 440 644 1027 and can also be accessed through its website. XSNX operates from 459 Columbus Avenue, New York, NY 10024, United States.

How many shares of XSNX are traded daily?

XSNX stock volume for the day was 10K shares. The average number of XSNX shares traded daily for last 3 months was 1.12K.

What is the market cap of XSNX currently?

The market value of XSNX currently stands at $12.33K with its latest stock price at $0.00 and 61.65M of its shares outstanding.

Employees	2
Beta	2.8
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	September
Sector	Healthcare
Industry	Biotechnology

XSNX Company Profile and Key Details

NovAccess Global

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics